medigraphic.com
ISSN 2954-3835 (Electronic)
ISSN 2683-2828 (Print)

2026, Number 2

<< Back Next >>

Cardiovasc Metab Sci 2026; 37 (2)

A comparative evaluation of sacubitril-valsartan and nebivolol-valsartan in left ventricular remodeling following chronic myocardial infarction in female Wistar rats

Pérez-García E, Valencia-Hernández I, Lezama-Martínez D, Ramírez-Hernández D, Garrido-Fariña GI, Ramírez-Hernández C, Reyes-Alvarado K, Hidalgo I, Flores-Monroy J

Language: English
References: 34
Page: 60-73
PDF size: 2885.10 Kb.


ABSTRACT

Cardiac fibrosis following a myocardial infarction (MI) leads to adverse left ventricular remodeling and heart failure, with distinct patterns observed in women. Despite having smaller infarcts and less profibrotic activity, women have a higher risk of post-MI mortality and heart failure. Since on therapies currently target fibrosis directly, studying these mechanisms is essential for developing and testing treatments, including approved heart failure drugs such as sacubitril–valsartan. This study aimed to compare and evaluate the combination of nebivolol-valsartan (NV) vs sacubitril-valsartan (SV) as a known treatment for chronic infarction in female rats; 26-weeks-old Wistar rats were used. The animals were divided into four groups (n = 6): 1) control (SHAM); 2) myocardial infarction (LADL); 3) LADL + sacubitril 30 mg/kg/day + valsartan 28 mg/kg/day (LADL + SV); 4) LADL + valsartan 30 mg/kg/day + nebivolol 5 mg/kg/day (LADL + NV). Infarct induction was performed by permanent ligation of the left anterior descending coronary artery. The treated groups received their treatments right after infarct induction for two weeks. The rats were euthanized by cervical dislocation and hearts and lungs were obtained from all groups for histology using Van Gieson and HE staining. The NV combination resulted in 50% mortality in animals, promoting pulmonary congestion and pleural effusion. Therefore, the administration of the NV combination at different times was proposed, after three and seven days post-infarction. This NV provocó una mortalidad de 50% en los animales, lo que favoreció la congestión pulmonar y el derrame pleural. Por lo tanto, se propuso la administración de la combinación de NV en diferentes momentos, a los tres y a los siete días tras el infarto. Esto dio lugar a seis grupos experimentales. Se observó una reducción de la tasa de mortalidad, así como de la hipertrofia y la fibrosis cardiaca, cuando la combinación de NV se administró siete días después de la ligadura. En conclusión, el sacubitril-valsartán parece ser una estrategia segura y eficaz para atenuar la fibrosis cardiaca y pulmonar tras el infarto en ratas hembras, mientras que la administración temprana de nebivolol-valsartán no se recomendaría de acuerdo a los resultados, ya que aparentemente podría generar más complicaciones postinfarto.


REFERENCES

  1. Martin SS, Aday AW, Allen NB, Almarzooq ZI,Anderson CAM, Arora P et al. Correction to: 2025Heart disease and stroke statistics: a report of US andglobal data from the American Heart Association.Circulation. 2025; 151 (25): e1096.

  2. Holtzman JN, Kaur G, Power JE, Barkhordarian M,Mares A, Goyal A et al. Underrepresentation of womenin late-breaking cardiovascular clinical trials. J WomensHealth (Larchmt). 2023; 32 (6): 635-640.

  3. Prabhu SD, Frangogiannis NG. The biological basisfor cardiac repair after myocardial infarction: frominflammation to fibrosis. Circ Res. 2016; 119 (1):91-112.

  4. Talman V, Ruskoaho H. Cardiac fibrosis in myocardialinfarction-from repair and remodeling to regeneration.Cell Tissue Res. 2016; 365 (3): 563-581.

  5. Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res.2021; 117 (6): 1450-1488.

  6. Ravassa S, López B, Treibel TA, San José G, Losada-Fuentenebro B, Tapia L et al. Cardiac fibrosis in heartfailure: focus on non-invasive diagnosis and emergingtherapeutic strategies. Mol Aspects Med. 2023; 93:101194.

  7. Gissler MC, Antiochos P, Ge Y, Heydari B, Grani C,Kwong RY. Cardiac magnetic resonance evaluation ofLV remodeling post-myocardial infarction: prognosis,monitoring and trial endpoints. JACC CardiovascImaging. 2024; 17 (11): 1366-1380.

  8. Aimo A, Panichella G, Barison A, Maffei S, Cameli M,Coiro S et al. Sex-related differences in ventricularremodeling after myocardial infarction. Int J Cardiol.2021; 339: 62-69.

  9. Dekleva M, Djordjevic A, Zivkovic S, Lazic JS.Specificities of myocardial infarction and heart failurein women. J Clin Med. 2024; 13 (23): 7319.

  10. Platz E, Merz AA, Jhund PS, Vazir A, Campbell R,McMurray JJ. Dynamic changes and prognostic valueof pulmonary congestion by lung ultrasound in acuteand chronic heart failure: a systematic review. Eur JHeart Fail. 2017; 19 (9): 1154-1163.

  11. Zannad F, Ferreira JP. Is sacubitril/valsartan antifibrotic?J Am Coll Cardiol. 2019; 73 (7): 807-809.

  12. Shi YJ, Yang CG, Qiao WB, Liu YC, Liu SY, DongGJ. Sacubitril/valsartan attenuates myocardialinflammation, hypertrophy, and fibrosis in rats withheart failure with preserved ejection fraction. Eur JPharmacol. 2023; 961: 176170.

  13. Varagic J, Ahmad S, Voncannon JL, Moniwa N,Simington SW, Brosnihan BK et al. Nebivolol reducescardiac angiotensin II, associated oxidative stressand fibrosis but not arterial pressure in salt-loadedspontaneously hypertensive rats. J Hypertens. 2012;30 (9): 1766-1774.

  14. Rajendran A, Minhas AS, Kazzi B, Varma B, ChoiE, Thakkar A et al. Sex-specific differences incardiovascular risk factors and implications forcardiovascular disease prevention in women.Atherosclerosis. 2023; 384: 117269.

  15. Medzikovic L, Aryan L, Eghbali M. Connecting sexdifferences, estrogen signaling, and microRNAs incardiac fibrosis. J Mol Med (Berl). 2019; 97 (10):1385-1398.

  16. Ramírez-Hernández D, López-Sanchez P, Rosales-Hernández MC, Fonseca-Coronado S, Flores-MonroyJ. Estrous cycle phase affects myocardial infarctionthrough reactive oxygen species and nitric oxide. FrontBiosci (Landmark Ed). 2021; 26 (12): 1434-1443.

  17. DiLorenzo MP, Grosse-Wortmann L. Myocardialfibrosis in congenital heart disease and the role of MRI.Radiol Cardiothorac Imaging. 2023; 5 (3): e220255.

  18. Valentin J, Frobert A, Ajalbert G, Cook S, Giraud MN.Histological quantification of chronic myocardialinfarct in rats. J Vis Exp. 2016; 118: 54914.

  19. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survivalafter an experimental myocardial infarction: beneficialeffects of long-term therapy with captopril. Circulation.1985; 72 (2): 406-412.

  20. Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G,Coste P et al. β blockers and mortality after myocardialinfarction in patients without heart failure: multicentreprospective cohort study. BMJ. 2016; 354: i4801.

  21. Xia QG, Chung O, Spitznagel H, Illner S, Janichen G,Rossius B et al. Significance of timing of angiotensinAT1 receptor blockade in rats with myocardialinfarction-induced heart failure. Cardiovasc Res. 2001;49 (1): 110-117.

  22. Liu Y, Zhong C, Si J, Chen S, Kang L, Xu B. The impactof Sacubitril/Valsartan on cardiac fibrosis early aftermyocardial infarction in hypertensive rats. J Hypertens.2022; 40 (9): 1822-1830.

  23. Torrado J, Cain C, Mauro AG, Romeo F, Ockaili R,Chau VQ et al. Sacubitril/valsartan averts adversepost-infarction ventricular remodeling and preservessystolic function in rabbits. J Am Coll Cardiol. 2018;72 (19): 2342-2356.

  24. Gabriel-Costa D. The pathophysiology of myocardialinfarction-induced heart failure. Pathophysiology.2018; 25 (4): 277-284.

  25. Xiao F, Wang L, Liu M, Chen M, He H, Jia Z et al.Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κBpathway in cardiomyocytes. Arch Biochem Biophys.2022; 730: 109415.

  26. Sui X, Wei H, Wang D. Novel mechanism of cardiacprotection by valsartan: synergetic roles of TGF-β1 andHIF-1α in Ang II-mediated fibrosis after myocardialinfarction. J Cell Mol Med. 2015; 19 (8): 1773-1782.

  27. Zhang Z, Ding L, Jin Z, Gao G, Li H, Zhang L et al.Nebivolol protects against myocardial infarction injuryvia stimulation of beta 3-adrenergic receptors and nitricoxide signaling. PLoS One. 2014; 9 (5): e98179.

  28. Leask A. Potential therapeutic targets for cardiacfibrosis: TGFbeta, angiotensin, endothelin, CCN2, andPDGF, partners in fibroblast activation. Circ Res. 2010;106 (11): 1675-1680.

  29. Vaskova E, Ikeda G, Tada Y, Wahlquist C, Mercola M,Yang PC. Sacubitril/valsartan improves cardiac functionand decreases myocardial fibrosis via downregulationof exosomal miR-181a in a rodent chronic myocardialinfarction model. J Am Heart Assoc. 2020; 9 (13):e015640.

  30. Burke RM, Lighthouse JK, Mickelsen DM, Small EM.Sacubitril/valsartan decreases cardiac fibrosis in leftventricle pressure overload by restoring PKG signalingin cardiac fibroblasts. Circ Heart Fail. 2019; 12 (4):e005565.

  31. Chen Y, Guo H, Xu D, Xu X, Wang H, Hu X et al. Leftventricular failure produces profound lung remodelingand pulmonary hypertension in mice: heart failurecauses severe lung disease. Hypertension. 2012; 59(6): 1170-1178.

  32. Perros F, Ranchoux B, Izikki M, Bentebbal S, HappéC, Antigny F et al. Nebivolol for improving endothelialdysfunction, pulmonary vascular remodeling, and rightheart function in pulmonary hypertension. J Am CollCardiol. 2015; 65 (7): 668-680.

  33. Zhou M, Meng L, He Q, Ren C, Li C. Valsartanattenuates LPS-induced ALI by modulating NF-κBand MAPK pathways. Front Pharmacol. 2024; 15:1321095.

  34. Jin HK, Yang RH, Thornton RM, Chen YF, JacksonR, Oparil S. Atrial natriuretic peptide lowerspulmonary arterial pressure in hypoxia-adaptedrats. J Appl Physiol (1985). 1988; 65 (4): 1729-1735.




2020     |     www.medigraphic.com